Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients

S. Hashi, Satohiro Masuda, M. Kikuchi, M. Uesugi, I. Yano, T. Omura, A. Yonezawa, Y. Fujimoto, K. Ogawa, T. Kaido, S. Uemoto, K. Matsubara

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Therapeutic drug monitoring (TDM) and subsequent dosage adjustment for individual patients in the treatment with tacrolimus are required after liver transplantation to prevent rejection and over-immunosuppression, which leads to severe infection and adverse reactions including nephrotoxicity. The purpose of this study was to evaluate the analytical performance among commercially available immunoassay methods, which were microparticle enzyme immunoassay (MEIA), chemiluminescent enzyme immunoassay (CLIA), and affinity column-mediated immunoassay (ACMIA), compared with an assay using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In addition, the flow injection assay (FIA-MS/MS) was also evaluated to determine whether it could be available as a new method of analysis in tacrolimus therapy. The blood tacrolimus concentrations in samples from liver transplant recipients (n = 102) were measured using MEIA, CLIA, ACMIA, and LC-MS/MS. Additional blood samples from liver transplant recipients (n = 54) were analyzed using both FIA-MS/MS and LC-MS/MS. Because the assay performance and characteristics of MEIA, CLIA, ACMIA, and FIA-MS/MS are relatively different, the measured data should be carefully considered depending on the methodology.

Original languageEnglish
Pages (from-to)758-760
Number of pages3
JournalTransplantation Proceedings
Volume46
Issue number3
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Tacrolimus
Tandem Mass Spectrometry
Immunoenzyme Techniques
Immunoassay
Injections
Liver
Drug Monitoring
Liquid Chromatography
Liver Transplantation
Immunosuppression
Transplant Recipients
Therapeutics
Infection

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. / Hashi, S.; Masuda, Satohiro; Kikuchi, M.; Uesugi, M.; Yano, I.; Omura, T.; Yonezawa, A.; Fujimoto, Y.; Ogawa, K.; Kaido, T.; Uemoto, S.; Matsubara, K.

In: Transplantation Proceedings, Vol. 46, No. 3, 01.01.2014, p. 758-760.

Research output: Contribution to journalArticle

@article{13495d699f4d4bab90939aed079b55a7,
title = "Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients",
abstract = "Therapeutic drug monitoring (TDM) and subsequent dosage adjustment for individual patients in the treatment with tacrolimus are required after liver transplantation to prevent rejection and over-immunosuppression, which leads to severe infection and adverse reactions including nephrotoxicity. The purpose of this study was to evaluate the analytical performance among commercially available immunoassay methods, which were microparticle enzyme immunoassay (MEIA), chemiluminescent enzyme immunoassay (CLIA), and affinity column-mediated immunoassay (ACMIA), compared with an assay using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In addition, the flow injection assay (FIA-MS/MS) was also evaluated to determine whether it could be available as a new method of analysis in tacrolimus therapy. The blood tacrolimus concentrations in samples from liver transplant recipients (n = 102) were measured using MEIA, CLIA, ACMIA, and LC-MS/MS. Additional blood samples from liver transplant recipients (n = 54) were analyzed using both FIA-MS/MS and LC-MS/MS. Because the assay performance and characteristics of MEIA, CLIA, ACMIA, and FIA-MS/MS are relatively different, the measured data should be carefully considered depending on the methodology.",
author = "S. Hashi and Satohiro Masuda and M. Kikuchi and M. Uesugi and I. Yano and T. Omura and A. Yonezawa and Y. Fujimoto and K. Ogawa and T. Kaido and S. Uemoto and K. Matsubara",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.transproceed.2013.11.060",
language = "English",
volume = "46",
pages = "758--760",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients

AU - Hashi, S.

AU - Masuda, Satohiro

AU - Kikuchi, M.

AU - Uesugi, M.

AU - Yano, I.

AU - Omura, T.

AU - Yonezawa, A.

AU - Fujimoto, Y.

AU - Ogawa, K.

AU - Kaido, T.

AU - Uemoto, S.

AU - Matsubara, K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Therapeutic drug monitoring (TDM) and subsequent dosage adjustment for individual patients in the treatment with tacrolimus are required after liver transplantation to prevent rejection and over-immunosuppression, which leads to severe infection and adverse reactions including nephrotoxicity. The purpose of this study was to evaluate the analytical performance among commercially available immunoassay methods, which were microparticle enzyme immunoassay (MEIA), chemiluminescent enzyme immunoassay (CLIA), and affinity column-mediated immunoassay (ACMIA), compared with an assay using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In addition, the flow injection assay (FIA-MS/MS) was also evaluated to determine whether it could be available as a new method of analysis in tacrolimus therapy. The blood tacrolimus concentrations in samples from liver transplant recipients (n = 102) were measured using MEIA, CLIA, ACMIA, and LC-MS/MS. Additional blood samples from liver transplant recipients (n = 54) were analyzed using both FIA-MS/MS and LC-MS/MS. Because the assay performance and characteristics of MEIA, CLIA, ACMIA, and FIA-MS/MS are relatively different, the measured data should be carefully considered depending on the methodology.

AB - Therapeutic drug monitoring (TDM) and subsequent dosage adjustment for individual patients in the treatment with tacrolimus are required after liver transplantation to prevent rejection and over-immunosuppression, which leads to severe infection and adverse reactions including nephrotoxicity. The purpose of this study was to evaluate the analytical performance among commercially available immunoassay methods, which were microparticle enzyme immunoassay (MEIA), chemiluminescent enzyme immunoassay (CLIA), and affinity column-mediated immunoassay (ACMIA), compared with an assay using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In addition, the flow injection assay (FIA-MS/MS) was also evaluated to determine whether it could be available as a new method of analysis in tacrolimus therapy. The blood tacrolimus concentrations in samples from liver transplant recipients (n = 102) were measured using MEIA, CLIA, ACMIA, and LC-MS/MS. Additional blood samples from liver transplant recipients (n = 54) were analyzed using both FIA-MS/MS and LC-MS/MS. Because the assay performance and characteristics of MEIA, CLIA, ACMIA, and FIA-MS/MS are relatively different, the measured data should be carefully considered depending on the methodology.

UR - http://www.scopus.com/inward/record.url?scp=84899560585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899560585&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2013.11.060

DO - 10.1016/j.transproceed.2013.11.060

M3 - Article

C2 - 24767342

AN - SCOPUS:84899560585

VL - 46

SP - 758

EP - 760

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -